Navigation Links
FORMA Therapeutics teams with TGen Drug Development
Date:6/18/2012

WATERTOWN, Mass., and SCOTTSDALE, Ariz. June 18, 2012 FORMA Therapeutics and TGen Drug Development (TD2) today announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

TD2 is a subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), a world-renowned biomedical research institute.

FORMA and TD2 also announced that Daniel D. Von Hoff, M.D., F.A.C.P., TGen's Distinguished Professor and Physician-in-Chief, and Stephen Gately, Ph.D., President and Chief Scientific Officer at TD2, will serve as clinical advisors to FORMA.

FORMA Therapeutics targets essential cancer pathways to create transformative, small molecule cancer therapies. Its focus on early identification of potent tool compounds helps facilitate target validation, enabling the creation of a robust pipeline of new therapies in areas such as tumor metabolism, protein-protein interactions and epigenetics.

TD2's mission is to facilitate innovative drug development and move new, targeted compounds to patients as quickly as possible. TD2 applies cutting-edge preclinical tools, streamlined and efficient regulatory processes and unique, targeted clinical trial designs and strategies. The combination of cutting-edge science, clinical development expertise and access to patients will accelerate the development of new agents for patients.

"I am excited about the potential of this relationship between FORMA and TD2," said Dr. Von Hoff. "It will accelerate the creation of new molecules that could be placed in research programs, such as our US Oncology Research Phase I program, further accelerating development and getting the right treatment to the right patient as soon as possible."

"TD2 brings preclinical and clinical development capabilities to FORMA, filling the missing piece in our strategy to become a fully-integrated research and development organization, leading the creation of breakthrough medicines for cancer patients," said Steven Tregay, Ph.D., Chief Executive Officer of FORMA. "We welcome Drs. Von Hoff and Gately as advisors and their unprecedented experience and networks in oncology drug development."

"FORMA's pioneering approach to oncology small molecule drug discovery has been prolific in tackling intractable targets and establishing industry partnerships," said Dr. Von Hoff. "We look forward to bringing the experience of our team to the FORMA team to guide its discovery programs and develop these important new drugs for patients."

TD2 has helped transition more than 40 companies from discovery to clinical development over the past five years, and TD2 has collective experience in performing clinical studies on more than 400 new anti-cancer agents.

"Our oncology discovery programs span more than 30 drug targets per year, and we need a partner to help direct the right drugs to the right patient groups," said Kenneth Bair, Ph.D., Chief Scientific Officer and Head of Research and Development of FORMA. "The TD2 team provides unique access to genetically selected patient populations that will help us both discover and test personalized therapeutics."


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
2. Childhood obesity linked to math performance, MU researcher says
3. Men and Women With Cancer May Receive Different Fertility Information
4. Markle releases new resources for health information sharing implementation
5. New study identifies how information technology is used to solve global health challenges
6. Can a standard vision test predict nighttime driving performance?
7. New online portal, app provide information on tsunami zones in the Northwest
8. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
9. Red wine, fruit compound could help block fat cell formation
10. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier ... position. The former overall number one pick in the 2001 NFL Draft, to the ... the record for the most career rushing yards by a quarterback (6,109) and the ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin ... of Education Research Award. The award honors scholars exemplary in their capacity to ... scholar who has demonstrated the capacity to deepen the public’s understanding and appreciation ...
(Date:4/24/2017)... Seattle, Washington (PRWEB) , ... April 24, 2017 , ... ... T-Fal OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill ... than perhaps any other marketer in the last 25 years. , Now, due to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... that they are seeking public support to bring their novel lifesaving device for ... wearable device packed with medical-grade sensors, specially designed to read a child’s vital ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , April ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, ... Lens"), today announced the signing of a three-year ... Lens will deploy a dedicated sales team to ... the U.S., primarily focused in 13 states in ...
(Date:4/18/2017)... 2017 Research and Markets has announced ... Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... revenues as well as growth in the number of unit ... to market participants that design and manufacture molecular imaging equipment. ...
Breaking Medicine Technology: